Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression analysis of Human pancreatic cancer cell line Panc1 pretreated with DMSO and Clofibrate.

ABSTRACT: Investigation of whole genome gene expression level changes of Panc1 pretreated with Clofibrate, compared to Panc1 pretreated with DMSO.

ORGANISM(S): Homo sapiens

PROVIDER: GSE69650 | GEO | 2015/06/09

SECONDARY ACCESSION(S): PRJNA286102

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression analysis of Human pancreatic cancer cell line Panc1 pretreated with DMSO and Clofibrate.

Project description:Investigation of whole genome gene expression level changes of Panc1 pretreated with Clofibrate, compared to Panc1 pretreated with DMSO. Compare differentially expressed genes by analyzing mRNA profilings between DMSO and Clofibrate pretreating Panc1 cell.

2015-06-09 | E-GEOD-69650 | biostudies-arrayexpress

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells were pretreated with CM272 (400nM) or vehicle (0.01%DMSO) for 24 hours followed by incubation of TGFβ1 (5ng/ml) for another 24 hours.

2019-10-29 | GSE139504 | GEO

Homo sapiens

Project description:Expression analysis of Human pancreatic cancer cell line Panc1 pretreated with DMSO and Clofibrate.

| PRJNA286102 | ENA

Effect of Clofibrate on Rat Primary Hepatocytes.

Project description:This study provides an evaluation of changes in gene expression associated with clofibrate treatment of rat hepatocytes in vitro. Primary rat hepatocytes were treated for 24 and 48 hours with two doses (60 uM and 1 mM) of clobibrate and 1% DMSO vehicle control. Five replicates of each treatment were performed. Cells were then extracted and RNA processed for microarray analysis.

2012-08-28 | GSE40344 | GEO

Microarray profiling of pluripotent stem cell derived cardiomyocytes pretreated with DMSO, DHS (10µM final concentration) and co-incubation of DHS and curcumin (10µM final concentrations) for 3 consecutive days.

Project description:hCMs pretreated with DMSO : DMSO-1 and DMSO-2 hCMs pretreated with DHS: Sph1, Sph2 and Sph3 hCMs pretreated with DHS+ Curcumin: Sph+Cur1, Sph+Cur2 and Sph+Cur3

2019-03-22 | E-MTAB-7530 | biostudies-arrayexpress

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

| PRJNA579991 | ENA

Rat liver response to Clofibrate, DEHP or VPA

Project description:The project had 2 goals: 1) To evaluate the transcriptional response of 3 prototypical toxicants (Clofibrate, VPA, and DEHP) on rat lever. 2) To evaluate the impact pooling samples has on data analysis. Keywords = Clofibrate Keywords = Diethylhexyl phthalate Keywords = Phthalic acid bis(2-ethylhexyl ester) Keywords = Sodium Valproate Keywords = Valproic Acid Keywords = VPA Keywords = vehicle Keywords: other

2005-06-02 | GSE2303 | GEO

Differential expression of pancreatic cancer PANC1 cells treated with pilocarpine

Project description:Human Panc1 cells were treated with 1mM Pilocarpine and the differential expression measured by RNASeq

2018-12-26 | GSE102880 | GEO

RNA-seq in pancreatic cancer PANC1 cells

Project description:RNA-seq in pancreatic cancer PANC1 cells

| PRJNA542693 | ENA

Profiling the Panc1 pancreatic cancer cell line following Gemcitabine treatment using single cell RNA sequencing

Project description:Pancreatic ductal adenocarcinoma (PDAC) often presents at late clinical stages, and most patients are managed solely through palliative chemotherapy. With no approved treatment modalities for patients who progress on broad-spectrum chemotherapy, we set to identify druggable targets to prevent or reverse resistance to the first line anti-neoplastic Gemcitabine. In our first experiment, we used the well-established Panc1 cell line as an in vitro model of PDAC. Panc1 cells were incubated with a tolerable dose of Gemcitabine in vitro, and examined alterations in gene expression via single cell RNA sequencing. In our subsequent studies, we incubated Panc1 cells with increasing doses of Gemcitabine for several passages, until viable in approximately 10x the known IC50 value. These cells were designated Panc1-GR. Based on our observations in the prior experiment, Panc1-GR cells were compared to those treated with wither the Calmodulin inhibitor W-7, Calcium chelator BAPTA-AM, or the calcium channel blocker Amlodipine. Through these efforts, we hope to better understand the mechanisms of Gemcitabine resistance in PDAC, as well as introduce new therapeutic strategies to reverse drug resistant phenotypes in the clinic.

2022-03-21 | GSE186960 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data